| Display title | Chemistry:Ridazolol |
| Default sort key | Ridazolol |
| Page length (in bytes) | 2,262 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 804319 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>TextAI2 |
| Date of page creation | 21:20, 17 December 2022 |
| Latest editor | imported>TextAI2 |
| Date of latest edit | 21:20, 17 December 2022 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Ridazolol is a pharmaceutical drug acting as a beta adrenergic receptor antagonist. It was investigated in the 1980 and 90s for its effects on coronary heart disease and essential hypertension (high blood pressure).
It is not known to be marketed anywhere in the world. |
